Recent studies have centered on the overlap of GLP|GIP|GCGR stimulant therapies and DA neurotransmission. While GCGR activators are commonly employed for managing type 2 diabetes mellitus, their potential impacts on https://tesslgxp929838.blogdemls.com/41351736/emerging-gip-agonists-and-dopaminergic-modulation-a-contextual-overview